Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$0.37 +0.5%	$0.38	$0.22 ▼ $1.30	$8.08M	1	3.71 million shs	330,254 shs
HYPD Hyperion DeFi	$6.21 -5.6%	$9.20	$0.85 ▼ $52.00	$37.47M	2.42	637,488 shs	282,627 shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A
SELB Selecta Biosciences		$1.06	$0.81 ▼ $1.99	$136.76M	0.84	979,585 shs	2.77 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	+0.54%	-7.00%	-26.63%	-48.26%	-61.85%
HYPD Hyperion DeFi	-5.62%	-11.79%	-46.65%	+205.91%	-88.59%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
SELB Selecta Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADIL Adial Pharmaceuticals	2.4131 of 5 stars	3.8	2.0	0.0	0.0	3.1	0.0	0.6
HYPD Hyperion DeFi	0.3738 of 5 stars	1.0	0.0	0.0	0.0	2.3	0.8	0.6
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SELB Selecta Biosciences	1.1118 of 5 stars	0.0	0.0	0.0	4.5	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	3.50	Strong Buy	$8.00	2,050.54% Upside
HYPD Hyperion DeFi	2.00	Hold	$2.00	-67.79% Downside
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A
SELB Selecta Biosciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$0.26 per share	N/A
HYPD Hyperion DeFi	$60K	588.92	N/A	N/A	$6.56 per share	0.95
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A
SELB Selecta Biosciences	$110.78M	0.00	N/A	9.91	$0.61 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$13.20M	-$1.05	N/A	N/A	N/A	N/A	-191.31%	-153.59%	N/A
HYPD Hyperion DeFi	-$49.82M	-$58.40	N/A	N/A	N/A	-62,238.41%	-876.25%	-181.67%	N/A
PHXM PHAXIAM Therapeutics	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SELB Selecta Biosciences	$35.38M	-$0.22	N/A	N/A	N/A	-72.04%	-44.13%	-22.00%	N/A

Latest SELB, HYPD, PHXM, and ADIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	ADIL Adial Pharmaceuticals	-$0.22	-$0.18	+$0.04	-$0.18	N/A	N/A
8/13/2025	Q2 2025	HYPD Hyperion DeFi	N/A	-$2.50	N/A	-$2.50	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HYPD Hyperion DeFi	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A
SELB Selecta Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	5.02	5.02
HYPD Hyperion DeFi	0.20	0.91	0.91
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A
SELB Selecta Biosciences	0.21	4.18	4.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
HYPD Hyperion DeFi	25.84%
PHXM PHAXIAM Therapeutics	0.40%
SELB Selecta Biosciences	41.95%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	4.26%
HYPD Hyperion DeFi	10.86%
PHXM PHAXIAM Therapeutics	1.94%
SELB Selecta Biosciences	31.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	20	21.83 million	20.90 million	No Data
HYPD Hyperion DeFi	40	5.69 million	5.08 million	No Data
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data
SELB Selecta Biosciences	64	155.20 million	106.78 million	Optionable

SELB, HYPD, PHXM, and ADIL Headlines

Recent News About These Companies

2025 Poinsettias catalog available from Selecta One

January 31, 2025 | nurserymag.comN

2025 Poinsettias catalog available now from Selecta One

January 29, 2025 | greenhousemag.comG

Leigh Francis insists Bo Selecta! reboot will never happen

October 20, 2024 | msn.com

LISTEN: Firebeatz and Noise Cans Join Forces in “Selecta”

September 25, 2024 | runthetrap.comR

Leigh Francis in Leeds: Keith Lemon and Bo Selecta! star announces evening of laughter at Leeds Grand Theatre

September 23, 2024 | msn.com

Leigh Francis interview: Leeds comedian of Keith Lemon and Bo' Selecta! fame on his fear of being cancelled

September 20, 2024 | msn.com

Astellas licenses companion drug for Pompe gene therapy

September 8, 2024 | pharmaphorum.comP

Craig David spoke out on how Bo Selecta 'ruined his life'

May 15, 2024 | ladbible.comL

Craig David says Bo Selecta ‘ruined his life’

May 14, 2024 | joe.co.ukJ

Leigh Francis says Bo Selecta couldn’t be made today because ‘you’ve got to be mindful nowadays’

May 12, 2024 | joe.co.ukJ

Craig David says Leigh Francis' Bo Selecta! skit 'sent him down a dark road'

May 6, 2024 | msn.com

Selecta Biosciences files patent for enhanced gene therapy using viral vectors and immunosuppressants

March 12, 2024 | pharmaceutical-technology.comP

Selb, Germany - Weather Forecasts | Maps | News - Yahoo Weather

January 23, 2024 | yahoo.com

Nanotechnology in Massachusetts – companies, research, and degree programs

January 13, 2024 | nanowerk.comN

Cartesian Therapeutics Inc (RNAC)

December 15, 2023 | investing.com

Selecta Biosciences, Cartesian Therapeutics Merge to Create Public RNA Cell Therapy Firm

November 14, 2023 | precisionmedicineonline.comP

Further weakness as Selecta Biosciences (NASDAQ:SELB) drops 17% this week, taking five-year losses to 85%

November 14, 2023 | finance.yahoo.com

Pared-down Selecta merges with Maryland biotech

November 13, 2023 | bizjournals.com

Selecta Biosciences Merges With Cartesian To Focus On Autoimmune Cell Therapy

November 13, 2023 | msn.com

Selecta Biosciences Merges With Cartesian Therapeutics In All-stock Deal

November 13, 2023 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SELB, HYPD, PHXM, and ADIL Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

$0.37 +0.00 (+0.54%)

Closing price 08/20/2025 04:00 PM Eastern

Extended Trading

$0.38 +0.00 (+1.08%)

As of 05:06 AM Eastern

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Hyperion DeFi NASDAQ:HYPD

$6.21 -0.37 (-5.62%)

As of 08/20/2025 04:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 08/19/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Selecta Biosciences NASDAQ:SELB

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time